Beacon Policy Advisors warned investors that Medicare will not cover the powerful new weight loss drugs from Eli Lilly & Co. NVO, -6.61 % . Novo Norisk. prohibits Medicare to cover prescription drugs for weight-loss. The Beacon Report said that although some legislators on both sides of aisle support changing the laws to allow this coverage, it is unlikely that such legislation will be considered in the current Congress or the following one. The report stated that “our main rationale” is that Republicans preach personal responsibility, and they would not want to spend billions on something that people think should be done by themselves. The report stated that “certain Democrats may be worried about the costs implications for Medicare’s financial solvency.” They may also worry about the Centers for Medicare & Medicaid Services’ more stringent auditing of doctors’ prescribing practices and the Part D and Medicare Advantage prescription drug plans.